Indication
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age
Loading your page…
Loading your page…
Ductus Arteriosus, Patent
Marketing Authorisation Holder: Gen.Orph
EMA Authorisation: 16/02/2024
INN: ibuprofen
AI Drug & Interaction Analysis
Free account required
Ask Osler about Ibuprofen Gen.Orph: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.